LLY Eli Lilly and Company
LLY Eli Lilly and Company
Healthcare · Drug Manufacturers - General
Desk view
Market read
Scan convergence 4 scans as of 2026-08-17 2 bull 1 bear 1 neutral diverging
POC $1,030 · VWAP $965.77 · +22.5% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
3 related perspectives
LLY Price Structure
Loading timeframes…
Peers
Every watchlist LLY belongs to, members best 30-day change first — LLY highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech
@peptide-economy
@healthcare-scan
@healthcare
@biotech-scan
@insider-universe
Decision history
4 scored calls · newest first · projection
How to read this: Positive 30-day excess supports an enter call. For pass, avoid, sell, or exit calls, a positive number means the name kept rising after the call.
Against street estimates
How LLY's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about LLY from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 7 days ago · Aug 11
- Eli Lilly & Co. (LLY) to acquire Verve Therapeutics (VERV) for $10.50/sh Cash plus CVR
- Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
- LLY Stock Jumps After Q1 Earnings Beat, 2026 Guidance Raised
- Eli Lilly to acquire cancer drug maker Kelonia in deal worth up to $7B
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
LLY research tape
165 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.
Desk commentary
Authored analysis and challenge notes tied to LLY.
Obesity/GLP-1 vertical: the next-gen trade is an AI-discovery + tools barbell, not a pure drug-developer bet
mega-cap weekly dispersion by climate era — fixed-percent thresholds dilute